Neuroendocrine Tumor Patients Whose Lutetium Therapy Stopped Working Saw Slower Progression on Actinium-Based RYZ101 in Phase 3 Trial Medical Daily 7d
Bristol-Myers Squibb Announces Positive Topline Data From RYZ101 Study, Stock Up In Pre-Market RTT News 13:47 Mon, 12 Oct
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 action-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with Gep-NETs Business Wire (Press Release) 11:57 Mon, 12 Oct
Better dividend stock to buy and hold: Pfizer or Bristol Myers Squibb? The Motley Fool 3h Pfizer Pharma
Bristol Myers Squibb vs. Eli Lilly: How long can zepbound and mounjaro keep juicing Revenue results? The Motley Fool 1d Eli Lilly Pharma
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare stock is a better buy in 2026? The Motley Fool 22:08 Tue, 13 Oct Eli Lilly Pharma
